Jian Yu

This inventor holds 19 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Cell Signaling Technology, Inc., University of California. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jian Yu. Retrieved from https://idiyas.com/inventor/jian-yu-tqqut7rr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 9)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 51(Granted Patents)

Location History:

Hamilton, MA (US) (2010 - 2022)
San Diego, CA (US) (2017 - 2022)

Company Filing History:

13 out of 61

Cell Signaling Technology, Inc.

patents

6 out of 16,035

University of California

patents

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

ROR1-ROR2 Binding

Cancer Vaccines

Anaplastic Lymphoma Kinase

Lung Cancer Detection

NSCLC Treatment

Gene Defects

Tyrosine Phosphorylation

Metastasis Inhibition

Antibody Development

Tumor Treatment

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12286480 - Modulators of ROR1-ROR2 binding (2025-04-29),

2. 12162950 - Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis (2024-12-10),

3. 11505833 - Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer (2022-11-22),

4. 11312787 - Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis (2022-04-26),

5. 10955416 - Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancer (2021-03-23),

6. 10913798 - Modulators of ROR1-ROR2 binding (2021-02-09),

7. 10870892 - Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer (2020-12-22),

8. 10344096 - Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis (2019-07-09),

9. 10000568 - Compositions and methods for detecting EGFR in cancer (2018-06-19),

10. 9988688 - Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer (2018-06-05),

11. 9758591 - Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis (2017-09-12),

12. 9523130 - Methods of treating non-small cell lung carcinoma (NSCLC) (2016-12-20),

13. 8486645 - Gene defects and mutant ALK kinase in human solid tumors (2013-07-16),

14. 8481279 - Methods of treating lung cancer using inhibitors anaplastic lymphoma kinase (2013-07-09),

15. 8377642 - Gene defects and mutant ALK kinase in human solid tumors (2013-02-19),

Title: **Innovator Jian Yu: Advancing Cancer Detection Through Patented Inventions**

Introduction

Jian Yu, an inventive mind based in Hamilton, MA, has made significant contributions to cancer research through his 13 patents. Known for his pioneering work in molecular biology, Yu's innovations focus on detecting mutations related to lung cancer, particularly through the identification of anaplastic lymphoma kinase (ALK) fusion proteins.

Latest Patents

Yu's latest patents revolve around the detection of mutant anaplastic lymphoma kinase in human lung cancer. He has identified novel gene deletions and translocations on chromosome 2 that result in fusion proteins, such as the EML4-ALK fusion protein, which has been shown to drive the proliferation and survival of non-small cell lung carcinoma (NSCLC). These inventions provide isolated polynucleotides and vectors encoding mutant ALK kinase polypeptides. Furthermore, they include probes for detection, isolated mutant polypeptides, recombinant polypeptides, and reagents for identifying fusion and truncated polypeptides. Importantly, Yu's work enables methods for screening compounds that inhibit these proteins and offers strategies for inhibiting cancer progression characterized by mutant polynucleotides or polypeptides.

Career Highlights

Jian Yu's innovative journey is underscored by his role at Cell Signaling Technology, Inc., where he has contributed to the advancements in technologies related to cancer diagnostics. His work is instrumental in understanding the mutations that underlie various solid tumors, leading to improved detection and treatment approaches.

Collaborations

Throughout his career, Yu has collaborated with renowned researchers, including Ting-Lei Gu and Klarisa Rikova. These partnerships have bolstered his research, fostering an environment of innovation and collaboration that drives the field of cancer research forward.

Conclusion

Jian Yu stands as a prominent figure in the realm of cancer research, with a notable portfolio of patents that reflect his commitment to innovation. His discoveries, particularly regarding ALK mutations in lung cancer, hold promise for enhancing diagnostic capabilities and therapeutic strategies, paving the way for improved patient outcomes in oncological care.

Profile summary based on public USPTO records.